Skip to main content
    U

    Universe Pharmaceuticals Inc (UPC)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.43
    -0.08 (-5.30%)

    Market Cap: $7.59M

    Last updated: Nov 17, 2026 at 8:19 AM ET

    Universe Pharmaceuticals Inc (UPC) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Universe Pharmaceuticals reported revenue of $17.86M for the fiscal year ended Sep 30, 2025, down 22.4% from the year before. That year, net income was -$3.67M with a net margin of -20.6%, operating cash flow was -$5.05M and free cash flow was -$5.40M. The quarter ended Jun 30, 2026 had revenue of $9.04M and net income of -$1.55M.

    Revenue and Margins

    The operating margin was -16.3% in the fiscal year ended Sep 2025. Over the 7 years to Sep 2025, revenue fell from $28.51M, a compound annual decline of 6.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$17.86M-22.4%35.3%-16.3%-20.6%
    Sep 2024$23.02M-28.7%26.4%-34.8%-37.9%
    Sep 2023$32.31M-19.5%31.9%-10.9%-19.1%
    Sep 2022$40.14M-16.3%54.5%-17.5%-21.8%
    Sep 2021$47.98M+56.3%52.8%28.3%23.6%
    Sep 2020$30.70M-7.6%45.9%33.4%24.6%
    Sep 2019$33.23M+16.5%40.3%29.4%22.7%
    Sep 2018$28.51MN/A47.0%33.9%26.7%
    Annual, fiscal years ended Sep 2018 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss narrowed from the year before.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
    Revenue$17.86M$23.02M$32.31M$40.14M$47.98M$30.70M$33.23M$28.51M
    Cost of revenue$11.56M$16.95M$21.99M$18.25M$22.66M$16.61M$19.82M$15.11M
    Gross profit$6.30M$6.07M$10.32M$21.89M$25.33M$14.09M$13.41M$13.41M
    Research and development$671.76K$3.60M$4.86M$7.62M$5.47M$583.13K$618.44K$789.38K
    Operating income-$2.92M-$8.02M-$3.53M-$7.02M$13.59M$10.25M$9.75M$9.66M
    Net income-$3.67M-$8.73M-$6.16M-$8.74M$11.32M$7.56M$7.55M$7.60M
    EBITDAN/A-$7.36M-$3.18M-$6.40M$14.20M$10.61M$10.17M$10.11M
    Fiscal years ended Sep 2018 to Sep 2025

    Quarterly

    Line itemJun 2026Dec 2025Mar 2025Jun 2024Dec 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021
    Revenue$9.04M$8.71M$9.15M$12.88M$13.84M$18.47MN/A$15.94MN/A$24.20M$24.20M$23.69M
    Gross profit$3.23M$3.14M$3.16M$3.24M$4.06M$6.01MN/A$8.05MN/A$13.63M$13.63M$13.26M
    Operating income-$1.50M-$589.16K-$2.33M-$1.74M-$3.68M$149.25KN/A-$10.14MN/A$2.70M$2.70M$4.01M
    Net income-$1.55M-$387.30K-$3.28M-$13.10M-$5.45M-$715.43KN/A-$10.47MN/A$1.73M$1.73M$4.17M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded short-term debt of $9.26M by $24.34M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
    Total assets$69.30M$67.95M$53.29M$59.54M$70.14M$28.80M$17.84M$28.08M
    Current assets$53.60M$51.64M$36.81M$41.51M$50.48M$22.84M$12.23M$21.96M
    Cash and equivalents$33.59M$29.50M$5.29M$5.71M$8.08M$10.06M$3.18M$6.19M
    Total liabilities$13.17M$22.45M$13.75M$13.10M$11.21M$8.00M$5.45M$18.40M
    Short-term debt$9.26MN/A$5.48M$3.94M$4.33M$2.65M$2.52M$2.62M
    Long-term debtN/A$2.14MN/AN/AN/AN/AN/AN/A
    Shareholder equity$56.13M$45.50M$39.53M$46.44M$58.93M$20.80M$12.38M$9.68M
    Fiscal years ended Sep 2018 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$71.47M$71.47M$69.30M$69.30M$80.67M$67.95M$49.43M$49.43M$53.29M$41.72M$70.37M$70.37M
    Total liabilities$15.82M$15.82M$13.17M$13.17M$25.48M$22.45M$22.69M$22.69M$13.75M$13.75M$23.24M$23.24M
    Cash and equivalents$27.56M$27.56M$33.59M$33.59M$47.27M$29.50M$8.86M$8.86M$5.29M$5.29M$12.95M$12.95M
    Shareholder equity$55.65M$55.65M$56.13M$56.13M$55.18M$45.50M$26.74M$26.74M$39.53M$27.97M$47.13M$47.13M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
    Operating cash flow-$5.05M-$9.51M$1.12M-$1.31M-$2.06M$6.12M$13.20M$4.46M
    Capital expenditures$347.19K$363.09K$44.17K$93.70K$13.53M$51.80K$86.32K$145.09K
    Free cash flow-$5.40M-$9.87M$1.08M-$1.41M-$15.59M$6.06M$13.12M$4.31M
    Dividends paidN/AN/AN/A$0$0$0$16.00M$3.06M
    Investing cash flow-$341.81KN/A-$44.17K-$3.91M-$27.06M-$51.80K-$86.03K-$145.09K
    Financing cash flow$9.73M$33.95M-$1.39M$3.32M$26.58M$470.14K-$16.00M-$4.91M
    Fiscal years ended Sep 2018 to Sep 2025

    Quarterly

    Line itemJun 2026Dec 2025Mar 2025Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$4.30M-$7.61M$2.56M-$2.43M-$3.64MN/A$4.80M$2.40M-$7.90M
    Capital expenditures$311.03K$169.99K$96.78K$67.66K$43.52K$0$646$323$38.07K
    Free cash flow-$4.61M-$7.78M$2.46M-$2.50M-$3.68MN/A$4.80M$2.40M-$7.94M
    Last 9 quarters

    Frequently Asked Questions About UPC

    What is Universe Pharmaceuticals' annual revenue?

    Universe Pharmaceuticals reported revenue of $17.86M for the fiscal year ended Sep 30, 2025.

    How fast is Universe Pharmaceuticals' revenue growing?

    Revenue was down 22.4% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -23.7%.

    Is Universe Pharmaceuticals profitable?

    No. Universe Pharmaceuticals reported net income of -$3.67M for the fiscal year ended Sep 30, 2025, with a net margin of -20.6%.

    How much free cash flow does UPC generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$5.05M minus capital expenditures of $347.19K produced free cash flow of -$5.40M.

    How much debt does Universe Pharmaceuticals have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $9.26M and cash and equivalents of $33.59M.